Floatz logo

Metformin

Small Cell Lung Cancer Extensive Stage

Hunan Cancer HospitalSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

11 Active assets in the Small Cell Lung Cancer Extensive Stage cohort.

Asset / SponsorPhaseRating
Epirubicin
Henan Cancer Hospital
Phase 3B
mhb088c for
Qilu Pharmaceutical Co., Ltd.
Phase 3B
Irinotecan
Guangzhou Institute of Respiratory Disease
Phase 2CCC
I-Dxd
Merck Sharp & Dohme LLC
Phase 1/2CC
bi 853520
InxMed (Shanghai) Co., Ltd.
Phase 1/2CC

View all 14 →

Same molecule, other indications

Metformin is also rated in:

Metabolism and Nutrition DisorderDormant
A
Indicative ·
82 / 100
View asset →
prediabetes syndromeDormant
A
Indicative ·
81 / 100
View asset →
gestational diabetesDormant
A
Indicative ·
81 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →